Aarti Pharmalabs Limited

What Aarti Pharmalabs Limited does

Aarti Pharmalabs Limited (APL) is an Indian pharmaceutical and nutraceutical manufacturer that operates six manufacturing plants and two R&D centres, producing Active Pharmaceutical Ingredients (APIs), pharmaceutical intermediates, xanthine derivatives including synthetic caffeine, sulphur-based acid and allied products, and offering Contract Development and Manufacturing Organization (CDMO) services. Incorporated in 2019 and demerged from Aarti Industries Limited in 2022, APL is publicly listed on NSE (AARTIPHARM) and BSE (543748). The company serves four distinct customer segments: global generic pharmaceutical companies requiring APIs and intermediates with regulatory documentation, innovator pharma and biotech firms needing CDMO services for NCE development from clinical Phases I through commercial launch, beverages and nutraceutical companies sourcing caffeine and xanthine derivatives, and chemical industry buyers of sulphur-based alkylating agents.

APL's technical foundation rests on proprietary process chemistry capabilities including flow chemistry, continuous hydrogenation, photochemistry, high-pressure reactions (up to 100 kg/cm²), cryogenic reactions (down to -100°C), biocatalysis, and HPAPI manufacturing at OEL levels of 1-10 µg/m³. The company holds 40 US Drug Master Files and 20 Certificates of Suitability from EDQM, with 15+ years of regulatory compliance across USFDA, EU GMP, KFDA, COFEPRIS, and WHO GMP. APL controls 800+ KL of reactor volume and produces 3,600+ MT of caffeine annually, commanding 15-20% of global caffeine supply as the world's only integrated non-Chinese caffeine manufacturer and approximately 80% of India's domestic caffeine demand.

The business model is B2B and project-based: revenue is generated through quote-driven sales of APIs, intermediates, and chemicals with multi-year contracts for products carrying regulatory documentation (USDMF, EDMF, CEP), and through professional services fees for CDMO engagements across clinical and commercial phases. Distribution is predominantly direct export to regulated markets (USA, EU, Japan) with selective use of chemical distributors for acid and allied products. Backward integration into raw materials is a central cost strategy, reducing Chinese supply dependency. APL's FY26 consolidated revenue was Rs 1,819.4 crore with net profit of Rs 174.7 crore, marking a notable decline from FY25. Leadership is provided by Chairman Rashesh C. Gogri, Vice Chairperson & Managing Director Hetal Gogri Gala, and Managing Director Narendra Salvi, with the Gogri family retaining significant board influence following the 2022 demerger.

Name

Aarti Pharmalabs Limited

Legal name

Aarti Pharmalabs Limited

Website

https://aartipharmalabs.com

Company type

Public

Founded year

2019

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Aarti Pharmalabs Limited is an Indian pharmaceutical manufacturer producing APIs, intermediates, CDMO drug substances, synthetic caffeine, and xanthine derivatives across six plants, serving 500+ global generic pharma, innovator biotech, beverage, nutraceutical, and chemical industry customers in regulated markets.

Ownership category

akta.pro rank

Product category

Active Pharmaceutical Ingredients (APIs)

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833), Industrial Organic Chemicals (2860)

akta.pro primary industry

Small-Molecule API & Intermediates CDMO (HLAGABAA)

akta.pro secondary industries

Small-Molecule API Commercial Manufacturing (HLAGAHAB), Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM), Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI), Drug Substance–Drug Product Integrated CDMO (HLAGABAG)

Keywords

• Active pharmaceutical ingredients
• Pharmaceutical intermediates
• Contract drug manufacturing
• Xanthine derivatives manufacturing
• Caffeine manufacturing

Headquarters

HQ city

Mumbai

HQ country

India

HQ region

Asia

Offices10 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Infrastructure, Personnel, Technology or R&D, Marketing or Sales

Revenue model

1. API Manufacturing & Sales: Manufacture and sale of Active Pharmaceutical Ingredients including cardiovascular, anti-asthmatic, anti-cancer, CNS agents, and other therapeutic categories. Revenue generated from direct product sales to pharmaceutical companies globally.
2. Pharmaceutical Intermediates: Custom synthesis of intermediates for pharmaceutical clients, including regulated starting materials (RSM) and key starting materials (KSM) for API and NCE production.
3. CDMO Services: Contract Development and Manufacturing Organization services for drug substance/NCE development and manufacturing for innovator pharma and biotech companies, covering Ph-I/II/III, launch, and commercial phases.
4. Caffeine Products: Production and sale of caffeine anhydrous and caffeine granules for beverages, nutraceuticals, and pharmaceutical industries. Annual capacity up to 4000 MT.
5. Xanthine Derivatives: Manufacture of theophylline, aminophylline, etofylline, and other xanthine derivatives for pharmaceutical, beverage, and nutraceutical industries.
6. Acid & Allied Products: Sulphur-based chemicals including sulphuric acid, sulphur trioxide, oleum, dimethyl sulphate, diethyl sulphate, and sodium vinyl sulphonate for dyes, pharmaceuticals, and perfumery industries.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

Aarti Pharmalabs Limited manufactures and supplies Active Pharmaceutical Ingredients (APIs) across cardiovascular, anti-asthmatic, anti-cancer, CNS, and anti-diabetic therapeutic categories, alongside pharmaceutical intermediates, regulatory starting materials (RSM), and xanthine derivatives including synthetic caffeine. The company also offers Contract Development and Manufacturing Organization (CDMO) services covering clinical Ph-I/II/III through commercial manufacturing for innovator pharma and biotech customers, supported by two R&D centres and six manufacturing facilities accredited by USFDA, EU GMP, EDQM, KFDA, COFEPRIS, and WHO GMP.

Product overview

Aarti Pharmalabs Limited operates as a manufacturer of Active Pharmaceutical Ingredients (API), pharmaceutical intermediates, and xanthine derivatives, with integrated CDMO (Contract Development and Manufacturing Organization) services. The product portfolio includes: APIs across therapeutic categories such as cardiovascular (Ramipril, Quinapril), anti-asthmatic (Budesonide, Salmeterol), anti-cancer (Bicalutamide, Ifosfamide), CNS agents (Venlafaxine, Quetiapine), and anti-diabetic (Sitagliptin, Canagliflozin); custom pharmaceutical intermediates for major drug molecules; CDMO services for drug substance development through clinical to commercial phases; Caffeine products (Anhydrous and Granules) with 4000 MT annual capacity; Xanthine derivatives including Theophylline and Etofylline; and Acid & Allied products like Sulfuric Acid and Dimethyl Sulfate. The company has backward integration capabilities and serves regulated markets including USA, EU, and Japan.

Differentiator

Problem solved

Functional benefit

Products and services

• Active Pharmaceutical Ingredients (APIs) Manufacture and supply of generic Active Pharmaceutical Ingredients across cardiovascular, anti-asthmatic, anti-cancer, CNS, anti-diabetic and other therapeutic categories, manufactured at USFDA and EU GMP accredited facilities for global generic pharmaceutical companies.
• Pharmaceutical Intermediates Customized pharmaceutical intermediates for API manufacturing — including intermediates for Abemaciclib, Apixaban, Canagliflozin and other major drug molecules — offered at development, pilot, and commercial stages for pharmaceutical manufacturers.
• CDMO Services Contract Development and Manufacturing Organization services for drug substance / New Chemical Entity (NCE) development and manufacturing from clinical Ph-I/II/III through launch and commercial phases, offering HPAPI/cytotoxic handling, high-pressure, cryogenic, photochemistry, and flow chemistry capabilities for innovator pharma and biotech companies.
• Caffeine (Anhydrous and Granules) Manufacture and sale of synthetic Caffeine Anhydrous and Caffeine Anhydrous Granules for the pharmaceutical, beverage, and nutraceutical industries, with combined annual capacity up to 4,000 Metric Tons across Unit-III and Unit-V Tarapur, marking the company as the world's only integrated non-Chinese caffeine manufacturer.
• Xanthine Derivatives Manufacture of xanthine derivatives including Theophylline, Aminophylline, DMAU, Etofylline, and Dimethyl Urea for pharmaceutical and nutraceutical applications, with combined xanthine-derivatives capacity of 3,600 MT per annum.
• Acid & Allied Products Sulphur-based chemicals including Sulfur Trioxide, Sulfuric Acid, Oleum variants, Dimethyl Sulfate, Diethyl Sulfate, and Sodium Vinyl Sulfonate supplied to dyes, pharmaceuticals, and perfumery industries.

Quantifiable outcome

• 15-20% of global caffeine supply as world's only integrated non-Chinese caffeine manufacturer
• +4 more outcomes

Named customers5 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature8 records

Partnerships

One partnership is on record.

• Neighbourhood and multi-speciality hospitalssupportOthersAgreements with neighbourhood and multi-speciality hospitals for ensuring employees receive medical care as part of occupational health infrastructure. Also involves hiring of specialist physicians for employee health programs.

Scale indicators20 records

Recent moves8 records

Expansion highlights4 records

Direct peers

• Divi's Laboratories: Leading Indian API and intermediates manufacturer with global CDMO presence. Directly comparable to Aarti Pharmalabs in small-molecule API manufacturing, custom synthesis, and generics supply to regulated markets.
• Laurus Labs: Indian API and CDMO company with strong generics franchise and growing contract development services for innovator pharma. Comparable in API manufacturing scale and CDMO positioning to Aarti Pharmalabs.
• Suven Pharmaceuticals: Indian CDMO focused on small molecule NCE development and manufacturing for global innovator pharma. Closely comparable to Aarti Pharmalabs' CDMO business model and customer base (biotech/innovator pharma).
• Jubilant Pharmova: Indian pharmaceutical company with CDMO services (Jubilant Biosys, Contract Manufacturing) and API manufacturing. Competes with Aarti Pharmalabs in CDMO and radiopharmaceuticals-adjacent segments.
• Syngene International: India-based contract research and manufacturing organization offering drug substance development and manufacturing services. Comparable as a direct CDMO peer for innovator pharma/biotech customers.
• Piramal Pharma Solutions: Global CDMO offering API development, manufacturing, and complex chemistry services including HPAPIs. Comparable CDMO service portfolio and customer overlap with Aarti Pharmalabs' innovator pharma/biotech segment.
• Granules India: Indian API and pharmaceutical formulations manufacturer with focus on generic APIs. Comparable in generic API manufacturing scale and vertically integrated operations.
• CARBOGEN AMCIS (Dishman): Swiss-headquartered CDMO with Indian operations, specializing in API development, highly potent APIs, and complex chemistry. Comparable CDMO capabilities and HPAPI expertise.

Broad incumbents

• Aurobindo Pharma: Large Indian generic pharmaceutical company with significant API manufacturing operations serving global markets. Overlaps with Aarti Pharmalabs on generic APIs but operates a much broader finished dosage portfolio.
• Dr. Reddy's Laboratories: Major Indian pharma with API manufacturing business and active pharmaceutical services division. Comparable on generic API supply and growing CDMO services, though much larger and more diversified.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance12 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles15 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aarti Pharmalabs Limited